| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of medication use during lactation The information in this record pertains to the use of technetium-99m methphosphonate (technetium-99m methylene bisphosphonate; technetium-99m MDP) as a diagnostic agent. A subcommittee of the U.S. Nuclear Regulatory Commission recommended that, for the sake of simplified guidance, breastfeeding should be discontinued for 24 hours after administration of all technetium-99m diagnostic products, although this interval may be longer than actually needed. [1] The International Commission on Radiological Protection also recommends that breastfeeding need not be interrupted after administration of technetium-99m methphosphonate. [2] However, in order to follow the principle of “minimizing exposure as much as possible,” some experts recommend breastfeeding the infant before administration and discontinuing breastfeeding 3 to 6 hours after administration, then completely expressing and discarding the milk. If the mother has expressed and stored breast milk before the examination, it can be fed to the infant during the breastfeeding interruption. [3-5] The mother does not need to avoid close contact with the infant after receiving a regular clinical dose. [6] Mothers concerned about the level of radioactivity in their breast milk can request testing at a hospital's nuclear medicine center. They can resume breastfeeding when the radioactivity level is within safe limits. A method for measuring the radioactivity in breast milk and determining when it is safe for a mother to resume breastfeeding has been published. [7] For breastfeeding mothers exposed to Tc-99m in the workplace, no additional precautions are required beyond general radiation protection measures. [8] ◉ Effects on breastfed infants No relevant published information was found as of the revision date. ◉ Effects on lactation and breast milk No relevant published information was found as of the revision date. |
|---|---|
| References | |
| Additional Infomation |
Medronic acid is a 1,1-bisphosphonate composed of methane substituted with two phosphonic acid groups. It plays a role in maintaining bone mineral density and chelating bone. Medronic acid is a methylene-substituted bisphosphonate. It has an affinity for hydroxyapatite crystals in the bone matrix and can adhere to their surface. The drug accumulates at sites of mineralization in osteoid tissue and can complex with radioactive isotopes (e.g., technetium-99m) for bone imaging. See also: Disodium medronic acid (salt form). Tetrasodium medronic acid (salt form).
1. Methylene diphosphonic acid (also known as methylene diphosphonic acid) is used as a matrix additive in liquid chromatography-matrix-assisted laser desorption/ionization mass spectrometry (LC-MALDI-MS) to improve the salt tolerance of the detection system [1] 2. Application of methylphosphonic acid in LC-MALDI-MS Experimental procedure: First, prepare a matrix solution containing methylphosphonic acid (as an additive) and conventional MALDI matrix; then, after separating the analyte by liquid chromatography, mix the eluent with the prepared matrix solution; next, spot the mixed solution onto a MALDI target plate; finally, perform mass spectrometry detection. Adding menadione acid can effectively reduce the interference of salt ions (such as sodium and potassium ions) in the sample on the ionization efficiency of the analyte, thereby improving the detection sensitivity and signal-to-noise ratio of the target compound in the salt-containing sample [1]. In the salt tolerance test of the detection system, compared with the traditional MALDI matrix without menadione acid, the LC-MALDI-MS system with menadione acid as the matrix additive can still maintain a stable detection signal when the sample salt concentration increases to 50 mM, while the traditional system shows a significant signal decay or even disappearance when the salt concentration is 10 mM [1]. |
| Molecular Formula |
CH6O6P2
|
|---|---|
| Molecular Weight |
176.0023
|
| Exact Mass |
175.963
|
| CAS # |
1984-15-2
|
| Related CAS # |
25681-89-4 (di-hydrochloride salt);6145-29-5 (tetra-hydrochloride salt)
|
| PubChem CID |
16124
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
583.2±60.0 °C at 760 mmHg
|
| Melting Point |
197-199 °C(lit.)
|
| Flash Point |
306.5±32.9 °C
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
-4.11
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
9
|
| Complexity |
152
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(C([H])([H])P(=O)(O[H])O[H])(=O)(O[H])O[H]
|
| InChi Key |
MBKDYNNUVRNNRF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/CH6O6P2/c2-8(3,4)1-9(5,6)7/h1H2,(H2,2,3,4)(H2,5,6,7)
|
| Chemical Name |
phosphonomethylphosphonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1420.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (11.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (11.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (11.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6818 mL | 28.4091 mL | 56.8182 mL | |
| 5 mM | 1.1364 mL | 5.6818 mL | 11.3636 mL | |
| 10 mM | 0.5682 mL | 2.8409 mL | 5.6818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
